Individualized tacrolimus therapy for ulcerative colitis based on CYP3A5 SNPs

Individualized tacrolimus therapy for ulcerative colitis based on CYP3A5 SNPs - Tacrolimus therapy for ulcerative colitis based on CYP3A5 SNPs

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013694

Enrollment

Registered

2014-04-11

Start date

2014-05-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

determine CYP3A5 SNP status increase the initial dosage of tacrolimus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. individuals brom whom written informed consent was obtained 2. >=18 years old 3. patients who are going to take tacrolimus

Exclusion criteria

Exclusion criteria: 1. women who are pregnant, breastfeeding, or possible to be pregnant 2. individuals who are considered ineligible by the investigator

Design outcomes

Primary

Measure	Time frame
efficacy on day 7	—

Secondary

Measure	Time frame
blood concentration on day 3 time to reach the target concentration (10ng/ml)	—

Countries

Japan

Contacts

Public ContactTaku Kobayashi

Kitasato University Kitasato Institute Hospital Center for Advanced IBD Research and Treatment

kobataku@insti.kitasato-u.ac.jp03-3444-6161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026